Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd reports that its wholly-owned subsidiaries, Maxcure Nutravedics Limited, Pure and Cure Healthcare Private Limited, Malik Lifesciences Private Limited, and Nicholas Healthcare Limited, received assessment orders under Section 158BC of the Income Tax Act, 1961. The orders pertain to the block period from April 1, 2018, to March 12, 2025. The subsidiaries received demands of ₹15,23,84,730, ₹5,77,12,428, ₹80,49,432, and ₹44,97,058 respectively, due to disallowance of expenditures under Section 37(1) of the Act. The companies plan to appeal the orders, citing they are defendable and may not have a material financial impact.

Akums Drugs and Pharmaceuticals Ltd and its subsidiary Akumentis Healthcare Ltd received assessment orders from the Income Tax Department under Section 158BC of the Income Tax Act, 1961, for the block period from April 1, 2018, to March 12, 2025. Akums received a demand of ₹60,09,22,342, while Akumentis received a demand of ₹73,66,10,238, both due to disallowance of expenditures under Section 37(1) of the Act. Both companies plan to appeal the orders, citing that the demands are not sustainable and defendable.

Akums Drugs and Pharmaceuticals Ltd announced the resumption of 100% operations at its Haridwar manufacturing sites, effective May 18, 2026, following a four-day disruption. The disruption resulted in a delayed supply of approximately ₹20 Cr. The company anticipates recovering the production loss in the coming weeks and will not be filing any insurance claims related to the disruption.

Akums Drugs and Pharmaceuticals Ltd reports that manufacturing operations at its affected sites in Haridwar and its subsidiaries have resumed at over 70% capacity as of May 16, 2026, following an industry-wide disruption triggered by a review of minimum wages by state authorities in Uttarakhand. The company anticipates progressive improvement in productivity levels, with local authorities coordinating to restore normalcy. The company has industrial insurance to cover the loss of production.

Akums Drugs and Pharmaceuticals Ltd. has released a Monitoring Agency Report by CRISIL Ratings Limited for the quarter ended March 31, 2026, concerning the utilization of IPO proceeds. The report, in compliance with SEBI regulations, confirms no deviations from the IPO's stated objectives. The initial IPO size was ₹6,800 million, with revised offer expenses of ₹378.21 million, resulting in net proceeds of ₹6,421.80 million. Issue expenses paid till the quarter ended March 31, 2026, amounted to ₹377.23 million.

Akums Drugs & Pharmaceuticals Ltd. reported its Q4 and full-year FY26 results, showcasing healthy revenue and strong EBITDA growth. Q4 FY26 operating revenue reached ₹1,158 crore, a 9.7% YoY increase. Adj EBITDA stood at ₹152 crore, up 61.6% YoY, with margins improving to 13.1%. Adj PAT grew by 135% YoY to ₹83 crore. For the full year FY26, operating revenue was ₹4,359 crore, up 5.9% YoY, with Adj EBITDA increasing by 13.3% to ₹522 crore and Adj PAT growing by 27.3% to ₹276 crore. The board recommended a final dividend of ₹1 per equity share and a special dividend of ₹2 per equity share.

Akums Drugs and Pharmaceuticals Ltd has announced a temporary disruption in operations at some of its manufacturing sites in Haridwar due to labour unrest in the SIDCUL industrial area on May 14, 2026. The company is taking active measures to normalize operations and is in discussions with workers and local authorities to resolve the issue quickly and amicably. Further updates and impact assessment will be provided in due course.

Akums Drugs and Pharmaceuticals Ltd. has declared a final dividend of ₹1.00 per equity share and a special dividend of ₹2.00 per equity share for the financial year ended March 31, 2026, subject to shareholder approval. The record date for determining shareholder eligibility for the dividend is set for July 3, 2026. The dividends, if approved, will be paid within 30 days of shareholder approval at the 22nd Annual General Meeting scheduled for July 10, 2026.

Akums Drugs and Pharmaceuticals Ltd announced changes in senior management personnel, effective May 14, 2026. Mr. V Jagannathan, President – HR, has been appointed as Senior Management Personnel. Simultaneously, Mr. Arvind Srivastava, also President – HR, has ceased to be a Senior Management Personnel of the Company. This decision was based on the recommendation of the Nomination and Remuneration Committee and approved by the Board of Directors.

Akums Drugs and Pharmaceuticals Ltd has appointed Mahajan & Aibara LLP, Chartered Accountants, as their Internal Auditors for the financial year 2026-27. This decision was made during the Board of Directors meeting held on May 14, 2026. The board also approved the re-appointment of M/s. Balwinder & Associates as Cost Auditors and recommended final and special dividends for FY 2026.